Published in BMC Syst Biol on April 18, 2016
Leptin-Induced JAK/STAT Signaling and Cancer Growth. Vaccines (Basel) (2016) 0.82
A Review of mTOR Pathway Inhibitors in Gynecologic Cancer. Oxid Med Cell Longev (2017) 0.75
Pre-clinical evaluation of a themosensitive gel containing epothilone B and mTOR/Hsp90 targeted agents in an ovarian tumor model. J Control Release (2017) 0.75
Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc (2009) 137.99
mTOR signaling in growth control and disease. Cell (2012) 29.21
Cytoscape 2.8: new features for data integration and network visualization. Bioinformatics (2010) 26.76
An automated method for finding molecular complexes in large protein interaction networks. BMC Bioinformatics (2003) 15.42
Network medicine: a network-based approach to human disease. Nat Rev Genet (2011) 14.07
Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest (2008) 10.74
Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res (2008) 8.17
Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res (2005) 7.34
Neurotrophin-regulated signalling pathways. Philos Trans R Soc Lond B Biol Sci (2006) 7.18
Cancer drug resistance: an evolving paradigm. Nat Rev Cancer (2013) 6.77
Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer (2011) 5.28
Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer (2003) 4.96
PI3K and cancer: lessons, challenges and opportunities. Nat Rev Drug Discov (2014) 4.81
A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst (2000) 3.98
Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. J Clin Invest (2012) 3.64
Atypical PKCiota contributes to poor prognosis through loss of apical-basal polarity and cyclin E overexpression in ovarian cancer. Proc Natl Acad Sci U S A (2005) 2.96
Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. J Clin Invest (1997) 2.96
AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth. Oncogene (2004) 2.67
Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors. Cancer Res (2008) 2.62
Inhibition of phosphatidylinositol 3'-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Cancer Res (2002) 2.37
Mechanisms of chemoresistance in cancer stem cells. Clin Transl Med (2013) 2.20
Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway. Cancer Chemother Pharmacol (2013) 2.09
Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways. Drug Resist Updat (2011) 1.87
Complexities of TGF-β targeted cancer therapy. Int J Biol Sci (2012) 1.84
An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in mice. J Clin Invest (2012) 1.79
ATP-dependent transport of glutathione S-conjugates by the multidrug resistance-associated protein. Cancer Res (1994) 1.73
Gene expression profile for predicting survival in advanced-stage serous ovarian cancer across two independent datasets. PLoS One (2010) 1.58
mTOR is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary. Clin Cancer Res (2009) 1.39
Role of the Akt/mTOR survival pathway in cisplatin resistance in ovarian cancer cells. Biochem Biophys Res Commun (2010) 1.37
Therapeutic modulators of STAT signalling for human diseases. Nat Rev Drug Discov (2013) 1.33
Resistance to platinum-based chemotherapy is associated with epithelial to mesenchymal transition in epithelial ovarian cancer. Eur J Cancer (2012) 1.30
The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer. Gynecol Oncol (2015) 1.28
STAT3 and epithelial-mesenchymal transitions in carcinomas. JAKSTAT (2014) 1.24
First-line treatment for advanced ovarian cancer: paclitaxel, platinum and the evidence. Br J Cancer (2002) 1.24
Multi-gene expression predictors of single drug responses to adjuvant chemotherapy in ovarian carcinoma: predicting platinum resistance. PLoS One (2012) 1.23
Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group study. Gynecol Oncol (2011) 1.23
Pathway analysis of gene lists associated with platinum-based chemotherapy resistance in ovarian cancer: the big picture. Gynecol Oncol (2010) 1.22
Inhibition of the mammalian target of rapamycin (mTOR) by rapamycin increases chemosensitivity of CaSki cells to paclitaxel. Eur J Cancer (2006) 1.16
Combination of PI3K/mTOR inhibitors: antitumor activity and molecular correlates. Cancer Res (2011) 1.16
Gene regulatory network inference: evaluation and application to ovarian cancer allows the prioritization of drug targets. Genome Med (2012) 1.14
Treatment for recurrent ovarian cancer-at first relapse. J Oncol (2009) 1.08
Therapeutic strategy targeting the mTOR-HIF-1alpha-VEGF pathway in ovarian clear cell adenocarcinoma. Pathol Int (2009) 0.99
TrkB as a therapeutic target for ovarian cancer. Expert Opin Ther Targets (2009) 0.99
The PI3K/Akt/mTOR pathway in ovarian cancer: therapeutic opportunities and challenges. Chin J Cancer (2015) 0.99
Networking of differentially expressed genes in human cancer cells resistant to methotrexate. Genome Med (2009) 0.95
Inhibiting the mTOR pathway synergistically enhances cytotoxicity in ovarian cancer cells induced by etoposide through upregulation of c-Jun. Clin Cancer Res (2011) 0.92
From molecular signatures to predictive biomarkers: modeling disease pathophysiology and drug mechanism of action. Front Cell Dev Biol (2014) 0.91
Transforming omics data into context: bioinformatics on genomics and proteomics raw data. Electrophoresis (2006) 0.90
Mapping of molecular pathways, biomarkers and drug targets for diabetic nephropathy. Proteomics Clin Appl (2011) 0.90
Integrating systems biology sources illuminates drug action. Clin Pharmacol Ther (2014) 0.88
The role of ABC transporters in ovarian cancer progression and chemoresistance. Crit Rev Oncol Hematol (2015) 0.88
Sensitization of Cervical Cancer Cells to Cisplatin by Genistein: The Role of NFκB and Akt/mTOR Signaling Pathways. J Oncol (2012) 0.87
Noscapine sensitizes chemoresistant ovarian cancer cells to cisplatin through inhibition of HIF-1α. Cancer Lett (2011) 0.87
The mTORC2 component rictor contributes to cisplatin resistance in human ovarian cancer cells. PLoS One (2013) 0.86
Upregulation of the antiapoptotic factor Livin contributes to cisplatin resistance in colon cancer cells. Tumour Biol (2012) 0.86
Overexpression of β-catenin and cyclinD1 predicts a poor prognosis in ovarian serous carcinomas. Int J Clin Exp Pathol (2013) 0.86
A dependency graph approach for the analysis of differential gene expression profiles. Mol Biosyst (2009) 0.85
Ovarian cancer: a clinical challenge that needs some basic answers. PLoS Med (2009) 0.84
Protein interactome of muscle invasive bladder cancer. PLoS One (2015) 0.82
Functional molecular units for guiding biomarker panel design. Methods Mol Biol (2014) 0.81
Linking the ovarian cancer transcriptome and immunome. BMC Syst Biol (2008) 0.81
The anti-ovarian cancer activity by WYE-132, a mTORC1/2 dual inhibitor. Tumour Biol (2015) 0.79
Functional molecular units for guiding biomarker panel design. Methods Mol Biol (2014) 0.81